Chemistry:Acoramidis
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H17FN2O3 |
| Molar mass | 292.310 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Acoramidis (AG10) is an investigational transthyretin stabilizer developed to treat transthyretin amyloid cardiomyopathy. It is delivered by mouth. An alternative treatment is tafamidis.[1][2][3]
References
- ↑ "Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy". https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-demonstrates-potential-of-acoramidis-for-transthyretin-amyloid-cardiomyopathy.
- ↑ Masri, Ahmad; Aras, Mandar; Falk, Rodney H.; Grogan, Martha; Jacoby, Daniel; Judge, Daniel P.; Shah, Sanjiv Jayendra; Witteles, Ronald et al. (March 2022). "Long-Term Safety and Tolerability of Acoramidis (Ag10) in Symptomatic Transthyretin Amyloid Cardiomyopathy: Updated Analysis from an Ongoing Phase 2 Open-Label Extension Study" (in en). Journal of the American College of Cardiology 79 (9): 227. doi:10.1016/S0735-1097(22)01218-9.
- ↑ Campbell, Courtney M.; Zhang, Kathleen; Lenihan, Daniel J.; Witteles, Ronald (April 2022). "Developing Therapy for Transthyretin Amyloidosis". The American Journal of Medicine 135: S44–S48. doi:10.1016/j.amjmed.2022.01.002. PMID 35077703.
 |  |
